Media Contact: Shea Higgins +1 304-633-3396, firstname.lastname@example.org
MILWAUKEE, WI, USA – Use of continuous intracerebroventricular (i.c.v.) administration of anaerobic dopamine (A-dopamine) showed a significant reduction in dyskinesias in a study released today at International Congress of Parkinson’s Disease and Movement Disorders® in Madrid, Spain.
Long-term use of levodopa/carbidopa often leads to development of unwanted motor symptoms in patients with Parkinson’s disease. These unwanted motor symptoms are termed levodopa-induced dyskinesias. Many alternate therapy options have been investigated as ways to stave off dyskinesia.
Moreau et al. and colleagues developed early clinical trials to assess the practicality of using i.c.v administration of dopamine. These early investigations failed due to the accelerated dopamine oxidation and tachyphylacxia. Their most recent investigation sought to investigate the safety and efficacy of i.c.v. of A-dopamine treatment versus the standard oral treatment in treating levodopa-related complications (LDRC). A total of four patients were assessed over two 1-month periods in an open-label randomized trial. Use of i.c.v. A-dopamine showed a greater reduction in dyskinesias compared to the standard oral treatment.
Stella Papa, Professor in the Department of Neurology at the Emory School of Medicine, responded to this study, “It is a significant result in four patients, which deserves attention. An alternative to oral treatment that reduces dyskinesias and ‘off’ periods between 80% to almost disappearance has a large effect. Results also show dose-dependent effect size, adding support to the data.”
Full abstract text: mdsabstracts.org. Reference #: 1030
# # #
About the 2022 MDS International Congress of Parkinson’s Disease and Movement Disorders®:
The MDS International Congress is the premier annual event to advance the clinical and scientific discipline of Movement Disorders, including Parkinson’s disease. Convening thousands of leading clinicians, scientists and other health professionals from around the globe, the International Congress will introduce more than 1,500 original scientific abstracts and provide a forum for education and collaboration on latest research findings and state-of-the-art treatment options.
About the International Parkinson and Movement Disorder Society:
The International Parkinson and Movement Disorder Society (MDS), an international society of over 11,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit www.movementdisorders.org.